158 related articles for article (PubMed ID: 17712588)
21. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
[TBL] [Abstract][Full Text] [Related]
22. Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation.
Krishnaswami A; Albers KB; Fross RD; Jang JJ; Berkheimer SB; Kwai Ben VC; Vandeneeden SK
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):276-80. PubMed ID: 22231899
[TBL] [Abstract][Full Text] [Related]
23. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
Roth J; Ulmanová O; Růzicka E
Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
25. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
Van Camp G; Flamez A; Cosyns B; Goldstein J; Perdaens C; Schoors D
Neurology; 2003 Sep; 61(6):859-61. PubMed ID: 14504342
[TBL] [Abstract][Full Text] [Related]
26. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.
Apostolakis EE; Baikoussis NG; Tselikos D; Koniari I; Prokakis C; Fokaeas E; Karanikolas M
J Cardiothorac Surg; 2009 Nov; 4():65. PubMed ID: 19912629
[TBL] [Abstract][Full Text] [Related]
27. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
[No Abstract] [Full Text] [Related]
28. Valvular heart disease in patients taking pergolide.
Waller EA; Kaplan J; Heckman MG
Mayo Clin Proc; 2005 Aug; 80(8):1016-20. PubMed ID: 16092580
[TBL] [Abstract][Full Text] [Related]
29. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
30. Bromocriptine use and the risk of valvular heart disease.
Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
[TBL] [Abstract][Full Text] [Related]
31. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
32. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
Tran T; Brophy JM; Suissa S; Renoux C
CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
[TBL] [Abstract][Full Text] [Related]
33. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Chaudhuri KR; Dhawan V; Basu S; Jackson G; Odin P
Mov Disord; 2004 Dec; 19(12):1522-3. PubMed ID: 15515009
[No Abstract] [Full Text] [Related]
34. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
[TBL] [Abstract][Full Text] [Related]
35. [Drug-induced valve heart disease].
Tribouilloy C; Jobic Y
Rev Prat; 2016 Oct; 66(8):874-880. PubMed ID: 30512542
[TBL] [Abstract][Full Text] [Related]
36. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
37. Additional insights into pergolide-associated valvular heart disease.
Lanier WL
Mayo Clin Proc; 2003 Jun; 78(6):684-6. PubMed ID: 12934776
[No Abstract] [Full Text] [Related]
38. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
39. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.
Steiger M; Jost W; Grandas F; Van Camp G
J Neural Transm (Vienna); 2009 Feb; 116(2):179-91. PubMed ID: 19142570
[TBL] [Abstract][Full Text] [Related]
40. Dopamine agonists and valvular heart disease.
Linkova H; Ruzicka E; Penicka M
N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17447279
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
